Britain’s vote to leave the EU has ushered in a period of uncertainty over the new location of the European Medicines Agency (EMA). The opportunity for member states to host the new headquarters, which employs 890 skilled staff from across Europe and acts as a hub for the pharmaceutical industry, has set off a race between potential candidates.

Germany, Spain, France, Italy, Ireland, Poland, Denmark and Sweden have all expressed an interest in becoming the new host. However, the final decision will be taken by the EMA, in mutual agreement with representatives of EU member states.

Whatever the outcome, the team at Viglya and our network of partners will continue to offer pharmacovigilance and regulatory affairs solutions in line with the requirements of the EMA and European National Competent Authorities, including the UK Medicines and Healthcare Products Regulatory Agency (MHRA), providing global solutions for the development and marketing of medicines across Europe.

More info: EU rivals vie to wrest drug and banking agencies from London